Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia

被引：1

作者：

Jarusiewicz, Jamie A. ^{[1
]}

Yoshimura, Satoshi ^{[2
]}

Actis, Marisa ^{[1
]}

Li, Yong ^{[1
]}

Fu, Xiang ^{[1
]}

Yang, Lei ^{[1
]}

Narina, Shilpa ^{[3
,4
]}

Pruett-Miller, Shondra M. ^{[3
,4
]}

Zhou, Suiping ^{[5
]}

Wang, Xusheng ^{[5
]}

High, Anthony A. ^{[5
]}

Nishiguchi, Gisele ^{[1
]}

Yang, Jun J. ^{[2
]}

Rankovic, Zoran ^{[1
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Memphis, TN 38105 USA

[3] St Jude Childrens Res Hosp, Dept Cell & Mol Biol, Memphis, TN 38105 USA

[4] St Jude Childrens Res Hosp, Ctr Adv Genome Engn, Memphis, TN 38105 USA

[5] St Jude Childrens Res Hosp, Ctr Proteom & Metabol, Memphis, TN 38105 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 14期

关键词：

PROTEIN; ABSORPTION;

D O I：

10.1021/acs.jmedchem.4c00481

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of SJ45566, a potent and orally bioavailable LCK PROTAC.

引用

页码：11868 / 11884

页数：17

共 50 条

[31] Pediatric T-Cell Acute Lymphoblastic Leukemia
Karrman, Kristina
Johansson, Bertil
GENES CHROMOSOMES & CANCER, 2017, 56 (02): : 89 - 116
[32] CApSiZing T-cell acute lymphoblastic leukemia
Mandleywala, Komal
Herranz, Daniel
HAEMATOLOGICA, 2024, 109 (06)
[33] The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia
Chang, Yunchao
Keramatnia, Fatemeh
Ghate, Pankaj S.
Nishiguchi, Gisele
Gao, Qingsong
Iacobucci, Ilaria
Yang, Lei
Chepyala, Divyabharathi
Mishra, Ashutosh
High, Anthony A.
Goto, Hiroaki
Akahane, Koshi
Peng, Junmin
Yang, Jun J.
Fischer, Marcus
Rankovic, Zoran
Mullighan, Charles G.
BLOOD, 2023, 142 (07) : 629 - 642
[34] PDGFR-β As a New Therapeutic Target in T-Cell Acute Lymphoblastic Leukemia
De Coninck, Stien
De Smedt, Renate
Lintermans, Beatrice
Goossens, Steven
Van Vlierberghe, Pieter
BLOOD, 2022, 140 : 11513 - 11514
[35] Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia
Hind Medyouf
Hélène Alcalde
Caroline Berthier
Marie Claude Guillemin
Nuno R dos Santos
Anne Janin
Didier Decaudin
Hugues de Thé
Jacques Ghysdael
Nature Medicine, 2007, 13 : 736 - 741
[36] Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia
Medyouf, Hind
Alcalde, Helene
Berthier, Caroline
Guillemin, Marie Claude
dos Santos, Nuno R.
Janin, Anne
Decaudin, Didier
de The, Hugues
Ghysdael, Jacques
NATURE MEDICINE, 2007, 13 (06) : 736 - 741
[37] Aberrant signaling in T-cell acute lymphoblastic leukemia:: biological and therapeutic implications
Cardoso, B. A.
Girio, A.
Henriques, C.
Martins, L. R.
Santos, C.
Silva, A.
Barata, J. T.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2008, 41 (05) : 344 - 350
[38] AKR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - MODEL FOR HUMAN T-CELL LEUKEMIA
BORTIN, MM
TRUITT, RL
BIOMEDICINE, 1977, 26 (05): : 309 - 311
[39] Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia
Staal, Frank J. T.
Langerak, Anton W.
HAEMATOLOGICA, 2008, 93 (04) : 493 - 497
[40] T-Cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia
Mantadakis, Elpis
Danilatou, Vassiliki
Stiakaki, Eftichia
Paterakis, George
Papadhimitriou, Stefanos
Kalmanti, Maria
PEDIATRIC BLOOD & CANCER, 2007, 48 (03) : 354 - 357

← 1 2 3 4 5 →